English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The use of metformin in reproductive medicine has exploded since clinical trials showed that a metabolic medication improved reproductive abnormalities in women with polycystic ovary syndrome (PCOS) (1). Metformin soon became an essential element for restoring ovulation (2), curing infertility (3), preventing pregnancy loss (4), and reducing pregnancy complications such as gestational diabetes mellitus (GDM), preeclampsia, and preterm labor, all of which were linked to insulin resistance and systemic inflammation in PCOS (5). Metformin lost the mantel of a medication, to be used judiciously for specific indications, and became instead a new vitamin, vitamin M, to be used ubiquitously to enhance every reproductive process in women with PCOS.

Metformin during Pregnancy in Polycystic Ovary Syndrome: Another Vitamin Bites the Dust